[{"id":"1b7433f8-fdf4-4ed8-b6bd-286988acbcd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04521686","created_at":"2021-01-18T21:39:29.090Z","updated_at":"2024-07-02T16:34:37.926Z","phase":"Phase 1","brief_title":"Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT04521686","lead_sponsor":"Eli Lilly and Company","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • LY3410738"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"67ee693c-6b97-4b0f-b34b-6654a4861bbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04603001","created_at":"2021-01-19T20:30:51.296Z","updated_at":"2024-07-02T16:34:58.765Z","phase":"Phase 1","brief_title":"Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT04603001","lead_sponsor":"Eli Lilly and Company","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • LY3410738"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 07/03/2023","primary_completion_date":" 07/03/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"68997bd5-1ca2-4ac4-86f7-940964b6a1c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914742","created_at":"2021-01-18T19:16:33.428Z","updated_at":"2024-07-02T16:35:20.037Z","phase":"Phase 1/2","brief_title":"BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations","source_id_and_acronym":"NCT03914742","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Partruvix (pamiparib)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 01/03/2020","start_date":" 01/03/2020","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-02-09"},{"id":"04cc697b-a936-4795-aed4-1231c763328e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441514","created_at":"2022-07-01T20:56:41.287Z","updated_at":"2024-07-02T16:35:25.985Z","phase":"Phase 1","brief_title":"Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05441514","lead_sponsor":"City of Hope Medical Center","biomarkers":" KRAS • BRAF • NRAS • IDH2 • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • IDH2 mutation • NF1 mutation • RAS mutation • CBL mutation • IDH2 R140 • IDH2 R172","tags":["KRAS • BRAF • NRAS • IDH2 • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • IDH2 mutation • NF1 mutation • RAS mutation • CBL mutation • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 05/02/2025","study_completion_date":" 05/02/2025","last_update_posted":"2023-12-18"},{"id":"96fb0dcd-765e-4e2c-9b74-d45af74a8e91","acronym":"","url":"https://clinicaltrials.gov/study/NCT03537560","created_at":"2021-01-18T17:25:21.578Z","updated_at":"2024-07-02T16:35:38.344Z","phase":"","brief_title":"Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML","source_id_and_acronym":"NCT03537560","lead_sponsor":"Chang Gung Memorial Hospital","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH2 R140 • IDH2 R172","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH2 R140 • IDH2 R172"],"overall_status":"Completed","enrollment":" Enrollment 334","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2023-08-31"},{"id":"fecf6843-8422-4be0-ad2d-bbf921311b94","acronym":"HOVON150AML","url":"https://clinicaltrials.gov/study/NCT03839771","created_at":"2021-01-18T18:57:21.726Z","updated_at":"2024-07-02T16:36:24.976Z","phase":"Phase 3","brief_title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","source_id_and_acronym":"NCT03839771 - HOVON150AML","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" FLT3 • IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation • IDH1 R132 • UGT1A1*1*1 • FLT3 mutation + IDH1 mutation • IDH2 R140 • IDH2 R172 • UGT1A1 mutation","tags":["FLT3 • IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation • IDH1 R132 • UGT1A1*1*1 • FLT3 mutation + IDH1 mutation • IDH2 R140 • IDH2 R172 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 968","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2033","study_completion_date":" 03/01/2033","last_update_posted":"2021-09-01"}]